MERRILL LYNCH GREATER EUROPE INVESTMENT TRUST plc
All information is at 30 November 2007 and unaudited.
Performance at month end with net income reinvested
One Three One Since launch
Month Months Year (20Sep04)
Net asset value -1.2% 4.1% 16.3% 97.2%
Share price -4.3% 1.7% 13.8% 86.7%
FTSE World Europe ex UK -1.0% 5.8% 18.2% 87.6%
Sources: BlackRock and Datastream.
At month end
Net asset value (capital only): 189.99p
Net asset value (including income): 190.04p Includes net revenue of 0.05p
Share price: 179.75p
Discount to NAV (capital only): 5.4%
Discount to NAV (including income): 5.4%
Gearing: 1.5%
Net yield: 1.3%
Total assets: £231.1m
Ordinary shares in issue: 119,843,969
Benchmark
Sector Analysis Total Assets Index Country Analysis Total Assets
(%) (%) (%)
Financials 23.8 28.8 Germany 23.9
Health Care 11.5 6.7 France 12.2
Oil & Gas 11.3 6.4 Switzerland 10.5
Basic Materials 10.4 6.2 Netherlands 9.3
Utilities 9.9 8.3 Italy 8.6
Consumer Goods 9.4 14.1 Finland 5.8
Industrials 7.2 12.9 Spain 5.4
Telecommunications 6.2 7.0 Norway 4.2
Technology 4.5 4.4 Russia 3.8
Consumer Services 3.6 5.2 Emerging Europe 3.5
Other Investments 3.6 - Turkey 3.1
Net current liabilities (1.4) - Israel 2.1
Greece 2.0
Austria 1.5
Ireland 1.4
USA 1.3
UK 1.1
Luxembourg 0.9
Poland 0.8
Net current liabilities (1.4)
----- ----- -----
100.0 100.0 100.0
----- ----- -----
Ten Largest Equity Investments
Company Country of Risk
Banco Santander Spain
BlackRock Eurasian Frontiers Hedge Fund Emerging Europe
DaimlerChrysler Germany
Electricite de France France
E.On Germany
Intesa Sanpaolo Italy
Nokia Finland
Novartis Switzerland
Roche Holdings Switzerland
Siemens Germany
Commenting on the markets, James Macmillan, representing the Investment Manager
noted:
European equities corrected sharply in November as concerns about global credit
markets continued to cause market jitters. Another 25 basis point reduction in
the US Federal Reserve Bank's official interest rate at the end of October did
little to calm investors' nerves. Neither the European Central Bank nor the
Bank of England followed the lead of the Fed by easing monetary policy during
the month. Following a strong run, Emerging Europe underperformed the
developed European markets as investors' concerns grew over the knock-on impact
of a US slowdown. The FTSE World Europe ex UK Index (NDR) returned -1.0%
through November and the MSCI Emerging Europe returned -2.5% in Sterling terms.
The Company's NAV returned -1.2%, underperforming the reference index. The
contribution from the Emerging Europe region was positive, with the Company
benefiting from its holding in the Eurasian Frontiers Hedge Fund and also
successful stock selection in Russia. The Company's performance was adversely
impacted by positive gearing in a falling market.
During the month, the Company benefited from its exposure to defensive sectors,
in particular Deutsche Telecom; Pharma stocks, Novartis and Roche; Health Care
company, Fresenius; and Utilities, E.ON and Electricite de France. Other
positive contributors to performance included selective investments in
Industrials, Siemens; and Banks, Intesa Sanpaolo.
The Company's exposure to the Financial sector, particularly Diversified
Financials, Credit Suisse and Fortis, continued to be a drag in November as
investors remained concerned that the ongoing uncertainty in credit markets
would negatively impact the sector's earnings. Stock selection in the Retail
and Food, Beverage & Tobacco sectors was negative, notably the Company's
holdings in Unilever and German D-I-Y Company, Praktiker.
During the month, the Company reduced its holdings in Financials through the
sale of shares in insurance company Allianz and banks, EFG Eurobank and Bank of
Cyprus. The proceeds were used to increase holdings in defensive areas such as
Food, Pharmaceuticals and Utilities.
The Company continues to have a bias towards Financials, through banks, along
with energy, pharmaceuticals, materials and utilities. Exposure to Emerging
Europe increased during the month to finish at 13.3%, with the largest country
exposures being Turkey and Russia, along with the BlackRock Eurasian Frontiers
Hedge Fund which provides diversified exposure to the region. During the
month, the Company significantly reduced its net market exposure to 101.5%.
We remain positive on the prospects for European and Emerging European
equities. The key risk is that of global recession but if current consensus
expectations of continued growth in Emerging markets prove robust, then
European companies can continue to deliver profit growth on the back of sales
expansion and productivity benefits. The overall valuation of the European
equity market looks reasonable and there are some stocks in cyclical sectors
which look very cheap, after the recent market weakness. M&A is likely to
continue to be supportive as many sectors consolidate across borders within
Europe. We believe a combination of strong earnings growth and attractive
valuations should allow the market to make progress against what may be a more
challenging international backdrop.
Latest Latest information is available by typing www.blackrock.co.uk/its on the
internet, "BLRKINDEX" on Reuters, "BLRK" on Bloomberg or "8800" on Topic 3 (ICV
terminal).
19 December 2007
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.